Completed
A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers
NCT02643303
- Conditions
- Adenocarcinoma, Bladder Cancer, Breast Cancer, +65 more
- Locations
-
- Research Facility Atlanta, Georgia, United States
- Research Facility Lebanon, New Hampshire, United States
- Research Facility Buffalo, New York, United States
- Research Facility New York, United States